209784-85-0

Basic information

• Product Name: tert-butyl N-{2-[4-(aMinoMethyl)benzaMido]phenyl}carbaMate
• Synonyms: tert-butyl N-{2-[4-(aMinoMethyl)benzaMido]phenyl}carbaMate;[2-[[4-(AMinoMethyl)benzoyl]aMino]phenyl]-carbaMic Acid tert-Butyl Ester
• CAS NO: 209784-85-0
• Molecular Formula: C₁₉H₂₃N₃O₃
• Molecular Weight: 341.40422
• Product Categories: Amines, Aromatics, Chiral Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 209784-85-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl N-{2-[4-(aMinoMethyl)benzaMido]phenyl}carbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl N-{2-[4-(aMinoMethyl)benzaMido]phenyl}carbaMate(209784-85-0)
• EPA Substance Registry System: tert-butyl N-{2-[4-(aMinoMethyl)benzaMido]phenyl}carbaMate(209784-85-0)

Safety Data

• Hazardous Substances Data: 209784-85-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
tert-butyl N-2-[4-(aMinoMethyl)benzaMido]phenylcarbaMate is used as a reactant for the preparation of benzamide derivatives, which are known for their potential as enzyme inhibitors and anticancer agents. The compound's unique structure allows it to interact with specific enzymes and proteins, making it a valuable component in the development of new drugs for various medical conditions.
Used in Enzyme Inhibition:
In the field of enzyme inhibition, tert-butyl N-2-[4-(aMinoMethyl)benzaMido]phenylcarbaMate is used as a key reactant in the synthesis of benzamide derivatives. These derivatives have the potential to inhibit the activity of certain enzymes, which can be beneficial in treating various diseases and conditions. By targeting specific enzymes, these benzamide derivatives can help regulate biological processes and provide therapeutic effects.
Used in Anticancer Applications:
The compound is also used in the development of anticancer agents. Benzamide derivatives synthesized from tert-butyl N-2-[4-(aMinoMethyl)benzaMido]phenylcarbaMate have shown potential in targeting cancer cells and inhibiting their growth. This makes them a valuable tool in the ongoing research and development of new cancer treatments.

Upstream product

• 130029-61-7 4-[[(2,2,2-trifluoroacetyl)amino]methyl]benzoic acid 
• 209784-84-9 tert-butyl-(2-(4-((2,2,2-trifluoroacetamido)methyl)benzamido)phenyl)carbamate 
• 146651-75-4 tert–butyl (2–aminophenyl)carbamate 
• 876-08-4 p-(chloromethyl)benzoyl chloride 
• 1392327-85-3 tert-butyl N-(2-([4-(chloromethyl)benzoyl]amino)phenyl)carbamate 
• 150-13-0 4-amino-benzoic acid 
• 56-91-7 p-aminomethylbenzoic acid 

Downstream Products

• 1448350-40-0 tert-butyl N-{2-[4-(isothiocyanatomethyl)benzamido]phenyl}carbamate 
• 1448350-41-1 tert-butyl N-(2-{4-[({[(1S)-2-hydroxy-1-phenylethyl]carbamothioyl}amino)methyl]benzamido}phenyl)carbamate 
• 1448350-42-2 tert-butyl N-(2-{4-[({[(1R)-2-hydroxy-1-phenylethyl]carbamothioyl}amino)methyl]benzamido}phenyl)carbamate 
• 1448350-43-3 (S)-tert-butyl N-(2-(4-((3-(2-hydroxy-1-(4-hydroxyphenyl)ethyl)thioureido)methyl)benzamido)phenyl)carbamate 
• 1448350-44-4 tert-butyl N-(2-{4-[({[(2S)-1-hydroxy-3-phenylpropan-2-yl]carbamothioyl}amino)methyl]benzamido}phenyl)carbamate 
• 1448350-45-5 tert-butyl N-(2-{4-[({[(2R)-1-hydroxy-3-phenylpropan-2-yl]carbamothioyl}amino)methyl]benzamido}phenyl)carbamate 
• 1448350-46-6 (S)-tert-butyl N-(2-(4-((3-(2-hydroxy-2-phenylethyl)thioureido)methyl)benzamido)phenyl)carbamate 
• 1448350-47-7 (R)-tert-butyl N-(2-(4-((3-(2-hydroxy-2-phenylethyl)thioureido)methyl)benzamido)phenyl)carbamate 
• 1448350-48-8 tert-butyl N-(2-(4-((3-((1R,2S)-2-hydroxy-1,2-diphenylethyl)thioureido)methyl)benzamido)phenyl)carbamate 
• 1448350-49-9 tert-butyl N-(2-(4-((3-((1S,2R)-2-hydroxy-1,2-diphenylethyl)thioureido)methyl)benzamido)phenyl)carbamate 
• 1448350-50-2 N-(2-aminophenyl)-4-({[(4S)-4-phenyl-4,5-dihydro-1,3-thiazol-2-yl]amino}methyl)benzamide 
• 1448350-51-3 N-(2-aminophenyl)-4-({[(4R)-4-phenyl-4,5-dihydro-1,3-thiazol-2-yl]amino}methyl)benzamide 
• 1448350-52-4 (S)-N-(2-aminophenyl)-4-(((4-(4-hydroxyphenyl)-4,5-dihydrothiazol-2-yl)amino)methyl)benzamide 
• 1448350-53-5 N-(2-aminophenyl)-4-(([(4S)-4-benzyl-4,5-dihydro-1,3-thiazol-2-yl]amino)methyl)benzamide 

Relevant articles and documents

CRYSTALLINE FORMS OF ENTINOSTAT

Entinostat is a histone deacetylase inhibitor undergoing clinical investigation in multiple types of solid tumors, such as breast cancer, and hematologic cancers. Crystalline form D and E of Entinostat and crystal form A in high crystal purity are provided. Crystalline form D can be obtained in high chemical purity, exhibits improved water solubility and allows efficient purification of Entinostat with removal of coloured impurities. Processes for the preparation of such crystalline forms and of form A with improved chemical and crystal purity are also provided.

Discovery of multi-target anticancer agents based on HDAC inhibitor MS-275 and 5-FU

Histone deacetylases (HDACs) inhibitors have multiple effects targeting the cancer cells and have become one of the promising cancer therapeutics with possibly broad applicability. Combination of HDAC inhibitors with the cytotoxic fluorouracil (5-FU) show

Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors

Recent studies have revealed that several histone deacetylase (HDAC) inhibitors, which are used to study/treat brain diseases, show low blood-brain barrier (BBB) penetration. In addition to low HDAC potency and selectivity observed, poor brain penetrance

Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit

The synthesis of a novel series of potent chiral inhibitors of histone deacetylase (HDAC) is described that contain a heterocyclic capping group and a N-(2-aminophenyl)benzamide unit that binds in the active site. In vitro assays for the inhibition of HDAC1, HDAC2, HDAC3-NCoR1, and HDAC8 by the N-(2-aminophenyl)benzamide 24a gave respective IC50 values of 930, 85, 12, and 4100 nM, exhibiting class I selectivity and potent inhibition of HDAC3-NCoR1. Both imidazolinone and thiazoline rings are shown to be effective replacements for the pyrimidine ring present in many other 2-(aminophenyl) benzamides previously reported, an example of each ring system at 1 μM causing an increase in histone H3K9 acetylation in the human cell lines Jurkat and HeLa and an increase in cell death consistent with induction of apoptosis. Inhibition of the growth of MCF-7, A549, DU145, and HCT116 cell lines by 24a was observed, with respective IC50 values of 5.4, 5.8, 6.4, and 2.2 mM.

Cell differentiation inducer

The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.